Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19Michael A. Thompson, KM Steve Lo, Elizabeth Robilotti et al.|JAMA Oncology|2021Cited by 185
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort StudyDonna R. Rivera, Jeremy L. Warner, Solange Peters et al.|Cancer Discovery|2020Cited by 138
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S. Davids, Jennifer R. Brown, Christine E. Ryan et al.|Journal of Clinical Oncology|2024Cited by 40
Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk DiseaseChristine E. Ryan, Matthew S. Davids, Benjamin L. Lampson et al.|Blood|2022Cited by 23
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S. Davids, Jennifer R. Brown, Christine E. Ryan et al.|Journal of Clinical Oncology|2025Cited by 1